Biotech Values

[pollyvonwog]

Momenta Pharmaceuticals Awarded U.S. Patent for Evaluating Mixtures of Low Molecular Weight Heparins by Chain Profiles or Chain Mapping

CAMBRIDGE, Mass., Sep 13, 2010 (GlobeNewswire via COMTEX) -- Momenta Pharmaceuticals, Inc. /quotes/comstock/15*!mnta/quotes/nls/mnta (MNTA 15.48, +0.19, +1.24%) , a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that on September 7, 2010 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,790,466, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping". The patent includes claims to methods of analyzing and processing enoxaparin that involve identifying chain sequence information.

"This patent provides further validation of our innovative approach to the characterization and ongoing quality control of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "Issuance of this patent strengthens our expanding portfolio of patents and pending applications related to methods and tools for the identification and analysis of enoxaparin, and provides intellectual property protection around enoxaparin sodium injection USP, also known as generic Lovenox(R)."

About Enoxaparin sodium injection, USP:

Enoxaparin, a low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis. Thrombosis is the formation of a blood clot in the blood vessels in the absence of bleeding. Enoxaparin is made up of a complex blend of low molecular weight substances (oligosaccharides) derived from heparins, and therefore requires sophisticated analytical methods on the part of the manufacturer to ensure accurate and reliable characterization, development and production. Enoxaparin sodium injection USP is marketed by Momenta's collaboration partner, Sandoz, Inc., a division of Novartis.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Momenta was founded in 2001 based on technology initially developed at the Massachusetts Institute of Technology and is headquartered in Cambridge, MA.

http://www.marketwatch.com/story/momenta-pharmaceuticals-awarded-us-patent-for-evaluating-mixtures-of-low-molecular-weight-heparins-by-chain-profiles-or-chain-mapping-2010-09-13?reflink=MW_news_stmp